[Indicators for quality evaluation of inpatient patient care in an ENT clinic].

[Quality assurance]. HNO (1998) 0.75

New insights to the MLL recombinome of acute leukemias. Leukemia (2009) 4.07

Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet (1998) 3.91

Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med (2000) 3.77

Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia (2008) 3.23

Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys (2001) 3.17

Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia (2009) 2.78

The MLL recombinome of acute leukemias in 2013. Leukemia (2013) 2.55

Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood (1999) 2.48

Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia (2009) 2.30

Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood (1994) 2.11

Phlebitis rate and time kinetics of short peripheral intravenous catheters. Infection (2004) 2.06

[Bilateral salivary gland swelling with pitfalls]. Med Klin (Munich) (1994) 2.03

Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. Blood (2000) 1.93

Prevalence, distribution, and viral load of human papillomavirus 16 DNA in tonsillar carcinomas. Cancer (2001) 1.85

Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting. Leukemia (2007) 1.79

Endoscopic cordectomy. A proposal for a classification by the Working Committee, European Laryngological Society. Eur Arch Otorhinolaryngol (2000) 1.76

Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90. Blood (1999) 1.75

Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage--a report of the Berlin-Frankfurt-Münster Group. J Clin Oncol (1995) 1.72

Rare benign tumors: laryngeal and hypopharyngeal lipomata. Ann Otol Rhinol Laryngol (2000) 1.65

Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements. Leukemia (2003) 1.64

Prognostic value of laryngeal electromyography in vocal fold paralysis. Arch Otolaryngol Head Neck Surg (2001) 1.62

A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma. Eur J Cancer (1995) 1.59

The favorable effect of activating NOTCH1 receptor mutations on long-term outcome in T-ALL patients treated on the ALL-BFM 2000 protocol can be separated from FBXW7 loss of function. Leukemia (2010) 1.56

Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90. Blood (2001) 1.55

The MLL recombinome of acute leukemias. Leukemia (2006) 1.51

Secondary neoplasms subsequent to Berlin-Frankfurt-Münster therapy of acute lymphoblastic leukemia in childhood: significantly lower risk without cranial radiotherapy. Blood (2000) 1.47

Down's syndrome in childhood acute lymphoblastic leukemia: clinical characteristics and treatment outcome in four consecutive BFM trials. Berlin-Frankfurt-Münster Group. Leukemia (1998) 1.44

Open partial horizontal laryngectomies: a proposal for classification by the working committee on nomenclature of the European Laryngological Society. Eur Arch Otorhinolaryngol (2014) 1.42

[Value of fine needle puncture cytology in neoplasms of the parotid gland]. HNO (2000) 1.41

[Temporal inconsistency of neuromyography of the facial nerve in healthy probands]. HNO (2000) 1.39

Resting energy expenditure, weight loss, and altered body composition in HIV infection. Nutrition (1996) 1.38

Evidence for genetic regulation of susceptibility to toxoplasmic encephalitis in AIDS patients. J Infect Dis (1996) 1.32

Indications, complications, and surgical techniques for pediatric tracheostomies--an update. J Pediatr Surg (2002) 1.32

Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95. Klin Padiatr (2005) 1.32

Treatment of dysfunction of the cricopharyngeal muscle with botulinum A toxin: introduction of a new, noninvasive method. Ann Otol Rhinol Laryngol (1994) 1.29

A powerful DNA extraction method and PCR for detection of microsporidia in clinical stool specimens. Clin Diagn Lab Immunol (1999) 1.26

Immunobiological diversity in infant acute lymphoblastic leukemia is related to the occurrence and type of MLL gene rearrangement. Leukemia (2007) 1.25

Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol. Leukemia (2009) 1.24

Polymorphisms within glutathione S-transferase genes (GSTM1, GSTT1, GSTP1) and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: a case-control study. Blood (2000) 1.23

[Corticosteroid-dependent reduction of leukocyte count in blood as a prognostic factor in acute lymphoblastic leukemia in childhood (therapy study ALL-BFM 83)]. Klin Padiatr (1987) 1.23

Secondary cytogenetic aberrations in childhood Philadelphia chromosome positive acute lymphoblastic leukemia are nonrandom and may be associated with outcome. Leukemia (2004) 1.21

Detection of microsporidia (Enterocytozoon bieneusi) in intestinal biopsy specimens from human immunodeficiency virus-infected patients by PCR. J Clin Microbiol (1995) 1.21

Cytoreduction and prognosis in childhood acute lymphoblastic leukemia. J Clin Oncol (1996) 1.18

Poor prognosis for P2RY8-CRLF2 fusion but not for CRLF2 over-expression in children with intermediate risk B-cell precursor acute lymphoblastic leukemia. Leukemia (2012) 1.16

Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster Study Group. Blood (1997) 1.16

Identification of germline susceptibility loci in ETV6-RUNX1-rearranged childhood acute lymphoblastic leukemia. Leukemia (2011) 1.15

[Application of the nasal provocation test on diseases of the upper airways. Position paper of the German Society for Allergology and Clinical Immunology (ENT Section) in cooperation with the Working Team for Clinical Immunology]. Laryngorhinootologie (2003) 1.15

CMV-antigenemia in peripheral blood for the diagnosis of CMV disease in HIV-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 1.14

Monitoring treatment response of childhood precursor B-cell acute lymphoblastic leukemia in the AIEOP-BFM-ALL 2000 protocol with multiparameter flow cytometry: predictive impact of early blast reduction on the remission status after induction. Leukemia (2008) 1.13

Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group. Leukemia (2000) 1.13

Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase. Ann Hematol (2003) 1.11

Incidence and clinical outcome of children with BCR/ABL-positive acute lymphoblastic leukemia (ALL). A prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL-BFM-90 and CoALL-05-92. Leukemia (1996) 1.10

Long-term results of large prospective trials in childhood acute lymphoblastic leukemia. Leukemia (2000) 1.08

Minimal residual disease (MRD) analysis in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: is it possible to avoid MRD testing? Leukemia (2008) 1.08

Single modality and multimodality treatment of nasal and paranasal sinuses cancer: a single institution experience of 229 patients. Eur J Surg Oncol (2006) 1.06

[Olfactory dysfunctions. Epidemiology and therapy in Germany, Austria and Switzerland]. HNO (2004) 1.06

Intensive treatment of children with acute lymphoblastic leukemia according to ALL-BFM-86 without cranial radiotherapy: results of Dutch Childhood Leukemia Study Group Protocol ALL-7 (1988-1991). Blood (1999) 1.04

Long-term results and risk profiles of patients in five consecutive trials (1979-1997) with stage 4 neuroblastoma over 1 year of age. Cancer Lett (2003) 1.04

Mutational screen reveals a novel JAK2 mutation, L611S, in a child with acute lymphoblastic leukemia. Leukemia (2006) 1.03

Consensus guidelines for microarray gene expression analyses in leukemia from three European leukemia networks. Leukemia (2006) 1.03

Inhibition of in vitro spontaneous apoptosis by IL-7 correlates with bcl-2 up-regulation, cortical/mature immunophenotype, and better early cytoreduction of childhood T-cell acute lymphoblastic leukemia. Blood (2000) 1.02

Pharmacokinetics of native Escherichia coli asparaginase (Asparaginase medac) and hypersensitivity reactions in ALL-BFM 95 reinduction treatment. Br J Haematol (2001) 1.02

Favorable outcome of B-cell acute lymphoblastic leukemia in childhood: a report of three consecutive studies of the BFM group. Blood (1992) 1.02

Folate metabolic gene polymorphisms and childhood acute lymphoblastic leukemia: a case-control study. Leukemia (2006) 1.01

Pharmacokinetic dose adjustment of Erwinia asparaginase in protocol II of the paediatric ALL/NHL-BFM treatment protocols. Br J Haematol (1999) 1.01

Successful treatment strategy for Ki-1 anaplastic large-cell lymphoma of childhood: a prospective analysis of 62 patients enrolled in three consecutive Berlin-Frankfurt-Munster group studies. J Clin Oncol (1994) 1.01

'Educational symposium on long-term results of large prospective clinical trials for childhood acute lymphoblastic leukemia (1985-2000)'. Leukemia (2010) 1.00

Pegylated asparaginase (Oncaspar) in children with ALL: drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols. Br J Haematol (2000) 1.00

Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC count and good response to prednisone. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster groups. J Clin Oncol (1997) 1.00

Polymorphisms within glutathione S-transferase genes and initial response to glucocorticoids in childhood acute lymphoblastic leukaemia. Pharmacogenetics (2000) 0.98

Ponte di Legno Working Group: statement on the right of children with leukemia to have full access to essential treatment and report on the Sixth International Childhood Acute Lymphoblastic Leukemia Workshop. Leukemia (2004) 0.98

CD95 (APO-1/Fas) mutations in childhood T-lineage acute lymphoblastic leukemia. Blood (1998) 0.97

Morphology of the human thyroglossal tract: a histologic and macroscopic study in infants and children. Ann Otol Rhinol Laryngol (2000) 0.97

[Health services research: essential for allocation decisions - joint statement]. Dtsch Med Wochenschr (2011) 0.96

Genetic evidence for latent Septata intestinalis infection in human immunodeficiency virus-infected patients with intestinal microsporidiosis. J Infect Dis (1996) 0.96

Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia. Haematologica (2000) 0.95

The seventh international childhood acute lymphoblastic leukemia workshop report: Palermo, Italy, January 29--30, 2005. Leukemia (2005) 0.95

Allogeneic hematopoietic SCT in children with ALL: current concepts of ongoing prospective SCT trials. Bone Marrow Transplant (2008) 0.95

Textured polydimethylsiloxane elastomers in the human larynx: safety and efficiency of use. J Biomed Mater Res (2000) 0.93

Dendritic cell deficiencies in pediatric acute lymphoblastic leukemia patients. Leukemia (2006) 0.93

Morphometric measurements of the cartilaginous larynx: An anatomic correlate of laryngeal surgery. Head Neck (1999) 0.93

Acute lymphoblastic leukemia of childhood: identification of two distinct regions of deletion on the short arm of chromosome 12 in the region of TEL and KIP1. Blood (1996) 0.93

Non-Hodgkin's lymphoma in adolescents: experiences in 378 adolescent NHL patients treated according to pediatric NHL-BFM protocols. Leukemia (2010) 0.93

Intermediate dose methotrexate is as effective as high dose methotrexate in preventing isolated testicular relapse in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol (1998) 0.92

Long-term survival of children with leukemia achieved by the end of the second millennium. Cancer (2001) 0.92

Intestinal microsporidiosis in patients with acquired immunodeficiency syndrome--report of three more German cases. Infection (1995) 0.91

Seroprevalence and disease association of antineutrophil cytoplasmic autoantibodies and antigens in HIV infection. Infection (1999) 0.91

Association of initial response to prednisone treatment in childhood acute lymphoblastic leukaemia and polymorphisms within the tumour necrosis factor and the interleukin-10 genes. Leukemia (2002) 0.91

Transoral laser surgery for laryngeal cancer: outcome, complications and prognostic factors in 275 patients. Eur J Surg Oncol (2008) 0.90

MRD at the end of induction therapy in childhood acute lymphoblastic leukemia: outcome prediction strongly depends on the therapeutic regimen. Leukemia (2001) 0.90

Primary mediastinal large B-cell lymphoma with sclerosis in pediatric and adolescent patients: treatment and results from three therapeutic studies of the Berlin-Frankfurt-Münster Group. J Clin Oncol (2003) 0.90

Infants with stage 4 neuroblastoma: the impact of the chimeric anti-GD2-antibody ch14.18 consolidation therapy. Klin Padiatr (2005) 0.90

Infant acute lymphoblastic leukemia - combined cytogenetic, immunophenotypical and molecular analysis of 77 cases. Leukemia (2002) 0.90

Magnetic resonance sialography. Otolaryngol Head Neck Surg (1999) 0.89

Clinical outcome of patients with childhood acute lymphoblastic leukaemia and an initial leukaemic blood blast count of less than 1000 per microliter. Klin Padiatr (2001) 0.89

Impaired renal function and tumor lysis syndrome in pediatric patients with non-Hodgkin's lymphoma and B-ALL. Observations from the BFM-trials. Klin Padiatr (1998) 0.88

Clinical risk factors for malnutrition in HIV-1-infected patients. AIDS (1993) 0.88

Invasive amoebiasis in two patients with AIDS and cytomegalovirus colitis. J Clin Microbiol (1997) 0.88

Gene expression shift towards normal B cells, decreased proliferative capacity and distinct surface receptors characterize leukemic blasts persisting during induction therapy in childhood acute lymphoblastic leukemia. Leukemia (2007) 0.88

Bone density measurements of the paranasal sinuses on plastinated whole-organ sections: anatomic data to prevent complications in endoscopic sinus surgery. Laryngoscope (1999) 0.87